Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

Table of Contents

April 1, 2014; Volume 55,Issue 4
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

  1. Jakobsen, Steen

    1. You have access
      Phosphodiesterase 10A PET Radioligand Development Program: From Pig to Human
      Christophe Plisson, David Weinzimmer, Steen Jakobsen, Sridhar Natesan, Cristian Salinas, Shu-Fei Lin, David Labaree, Ming-Qiang Zheng, Nabeel Nabulsi, Tiago Reis Marques, Shitij Kapur, Eiji Kawanishi, Takeaki Saijo, Roger N. Gunn, Richard E. Carson and Eugenii A. Rabiner
      Journal of Nuclear Medicine April 1, 2014, 55 (4) 595-601; DOI: https://doi.org/10.2967/jnumed.113.131409
  2. Johnson, Bruce F.

    1. You have access
      Functional Imaging of Oxidative Stress with a Novel PET Imaging Agent, 18F-5-Fluoro-l-Aminosuberic Acid
      Jack M. Webster, Christine A. Morton, Bruce F. Johnson, Hua Yang, Michael J. Rishel, Brian D. Lee, Qing Miao, Chittari Pabba, Donald T. Yapp and Paul Schaffer
      Journal of Nuclear Medicine April 1, 2014, 55 (4) 657-664; DOI: https://doi.org/10.2967/jnumed.113.126664
  3. Jones, Terry

    1. You have access
      Ultra Staging to Unmask the Prescribing of Adjuvant Therapy in Cancer Patients: The Future Opportunity to Image Micrometastases Using Total-Body 18F-FDG PET Scanning
      Patricia M. Price, Ramsey D. Badawi, Simon R. Cherry and Terry Jones
      Journal of Nuclear Medicine April 1, 2014, 55 (4) 696-697; DOI: https://doi.org/10.2967/jnumed.113.133892
Back to top
PreviousNext

In this issue

Journal of Nuclear Medicine: 55 (4)
Journal of Nuclear Medicine
Vol. 55, Issue 4
April 1, 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author

Issue highlights

  • Molecular Imaging Biomarkers for Oncology Clinical Trials
  • Quantitative Volumetric CT-Histogram Analysis in N-Staging of 18F-FDG–Equivocal Patients with Lung Cancer
  • 18F-FDG PET Scanning in Pulmonary Amyloidosis
  • Phosphodiesterase 10A PET Radioligand Development Program: From Pig to Human
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • MIRD Pamphlet No. 28, Part 1: MIRDcalc—A Software Tool for Medical Internal Radiation Dosimetry
  • Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine
  • Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
  • Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy
  • High-Temporal-Resolution Lung Kinetic Modeling Using Total-Body Dynamic PET with Time-Delay and Dispersion Corrections
More...
SNMMI

© 2025 SNMMI

Powered by HighWire